Danish drugmaker Novo Nordisk said it was seeing 'more patients than ever before'.
The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in profits on the back of surging demand for the drugs.
Net profits were 39.2bn kroner for the period from January to June, rising 43% from 27.5bn kroner a year earlier.Demand has been so strong the company is grappling with supply strains. Wegovy - an obesity treatment that is taken once a week - tricks people into thinking they're already full, so they end up eating less and losing weight., which has captivated Hollywood and the public more widely since it was approved by regulators in the US in 2021.
Media reports have described Wegovy and Ozempic - a diabetes treatment with similar effects - as "miracle" drugs that will spark a "revolution" in weight loss.reduce the risk of a stroke or heart attackThe firm hailed it a "landmark trial", saying it would change the way obesity is regarded and treated.
Wegovy was approved for NHS use earlier this year after research suggested users could shed more than 10% of their body weight.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial showsResults of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
Baca lebih lajut »
Novo Nordisk extends U.S. supply curbs on weight-loss drug WegovyNovo Nordisk will continue to restrict U.S. supplies of starter doses of its hugely popular Wegovy weight-loss drug in the coming quarters, it said on Thursday, as the company struggles to keep up with soaring U.S. demand.
Baca lebih lajut »
Wegovy-maker Novo Nordisk raises outlook as sales of its weight-loss drug soarThe Danish company's diabetes and obesity division performed particularly well, bolstered by interest in its blockbuster injection Wegovy.
Baca lebih lajut »
Wegovy-maker Novo Nordisk extends curb on supply of weight-loss drug, raises outlookThe Danish drugmaker confirmed that it will continue to restrict the lower-dose strengths of Wegovy as it strives to keep up with demand.
Baca lebih lajut »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Baca lebih lajut »
Novo's Wegovy Shows Heart Benefit Alongside Weight Loss in TrialNovo Nordisk, the maker of Wegovy, announced that a large study has demonstrated the cardiovascular benefits of the highly effective obesity treatment. This finding is significant as it allows the Danish company to expand its market beyond being perceived as a lifestyle drug. The positive results from the trial may also encourage insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy for a wider range of patients.
Baca lebih lajut »